Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
gunnebeoneday ...........
its been ONLY 3 weeks .......
Funding will take time ..........
even if there is an interested party ........
HOLD AND BUY THE DEALS AND BE PREPARED --- GEO
DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Pre-clinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to better design actual trials and are targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM).
q
GCBR ........
You're right ........
It isn't a drug, its a test .......
And DNAG will approach the FDA with test results .......
as soon as the clinicals are in ........
soooooooo .......
add this with YOUR OTHER DD .......
Which states: ...........
Mary Jane Q. Cross, an artist in Newport, New Hampshire, developed a permanent tremor on her right side after taking antidepressant Prozac 14 years ago. She now paints with her fingers as she cannot hold a brush. A year ago, she paid about $600 to Genelex, a company in Seattle, for genetic tests that showed she would have trouble tolerating certain drugs, possibly Prozac too. ‘‘Had I known that 14 years ago, I would not have used the drug,’’ Cross said.
Recently, when she had an emergency appendectomy, she advised the doctors to use a low dose of anesthesia based on her genetic test results. ‘‘My husband had to go home in the middle of the night to get the material, and make it clear to them that this was an important issue,’’ she said.
Scientists are finding numerous examples of variations in genes that help predict who will respond to a drug or who will suffer side effects. Most drug companies now routinely collect DNA samples from patients in clinical trials to look for such markers. In March, the FDA issued guidelines to encourage drug companies to pursue personalised medicine, and the agency is adding information about genetic tests to the labels of a few drugs.
AND WE ARE INTO A WHOLE NEW MARKET --- GEO
Money4nothin ........
You my friend are thinking .....
like so many of us here are thinking ......
THERE IS A REASON --- GEO
Virgil Hilts ......
It is just my opinion ......
"I do not see another reverse split" .......
These are my thoughts .......
our OS stand at just over 10% of AS ..........
we are generating revenue as stated in the last 10Q .......
Our revenue growth has increased Quarter after Quarter ......
There is great interest in PERSONALIZED MEDICINE ........
I EXPECT CONVENTIONAL INVESTMENT .........
We have GROWN four times our size in 3 months .......
with that we have aquired STREAMS OF DATA and PATENTS ......
The closer we come to our GOALS .......
The HIGHER the SP will be .........
at what we can accumulate, for just pennies .........
Long Term bodes well for investors ......
If it was Short Term .........
The SP would not be at these levels ........
Certain Individuals say "NO REVENUE" further DILUTION .....
I have told myself .......
REVENUE WILL COME SO WILL DILUTION ........
But not at the expense of another RS .......
We have been able to aquire so much with the dilution ....
we have experienced so far .........
With what DNAG is CAPABLE of doing .......
I don't care if we Dilute some more ..........
AS LONG AS IT ADDS VALUE --- GEO
Open your EYES .......
I can't even keep up ......
with whats going on with DNAPRINT GENOMICS ....lol
but the more that I hear ......
the WIDER my eyes become .......
in the words of Baden Powell ......
ALWAYS BE PREPARED --- GEO
Hopeless ......
Nothing for 2006 ..... lol
you make me laugh .....
first of all ......
I think we will find out .....
what big 50 company ......
we made "tickled pink" ......
with the testing of 60 patients .....
LOL --- GEO
ifida .....
I would also like to point out .......
7 new distibutors mentioned .......
in the last 10Q .......
AND MY GUESS IS J&J --- GEO
ifida ......
Am I correct to say that FAMILY TREE DNA......
uses ANCESTRYBYDNA ........
which is a product of DNAPRINT GENOMICS .......
EXCELLENT FIND --- GEO
Theo this is meant as a joke .........
The following NR should have read .........
Beautiful intellegent woman, seeks Private funding for DNAPRINT GENOMICS .......
HECK I WOULD GIVE HER MONEY .... LOL --- GEO
Look for Happy Days Ahead ......
With the M/A activity in the since late June .....
3 new labs have been brought on board ......
Several of them have been gathering/working on projects .....
That will now be OUR projects ........
Some in early stages, some in late stages ........
With the advantage of ADMIXMAP and the newly aquired Tech ......
We should be seeing some interesting devolpments ........
Our newly aquired staff and management are working hard ......
towards bringing DNAPRINT GENOMICS to the forefront .......
A leading role in the GENOMICS field ..........
So many doors, that when one opens, we are on our way .......
I am supporting DNAPRINT GENOMICS at these levels ........
because I believe they have what it takes to go forward .......
I will continue to add to my position ......
knowing that the Company is makeing great strides ......
in the devolpment of personal medicine .......
It is the future .......
and as Share Holders it is ......
OUR FUTURE --- GEO
In the U.S.A forensics is 500mil
and thats just in the U.S .....
And here is the update for DNAWITNESS from the 10Q .....
We continue to market our DNAWitness(TM) product through marketing to various
agencies, our attendance at trade shows and through our relationships with Lynn
Peavey catalog, Orchid Biosciences, and ReliaGene Technologies. We continue to
seek to develop other distributors of our services and products. During 2004,
our products, DNAWitness(TM) 2.0, RETINOME, and EURO-Witness 1.0 were featured
in the Lynn Peavey Company catalog and the Lynn Peavey Web site. We trained Lynn
Peavey Company personnel to establish and conduct seminars and training programs
for detectives, crime laboratory personnel and crime scene personnel on
DNAWitness(TM). Similarly, we have trained nearly 2,000 forensic personnel that
include detectives, prosecutors and forensic scientists about our technology and
its use. We anticipate continuing to train personnel on the use of our
technology and products throughout 2005. Because these are new products and
there are no similar products being marketed, we believe that forensic revenues
will continue to fluctuate as we continue to research the markets and refine our
sales and marketing strategy for our products. We have identified and applied
for several grants and submitted our technology for federal review for
applications that include human identification and terrorist tracking. We have
not experienced and do not anticipate any funding of our research and
development or deployment of our technology into any of these applications in
2005. We believe that the restraint of our sales in the forensics market does
not originate from a lack of desire to use the technology by the detective or
the prosecutor but rather a lack of funding for the increased staff that will be
required to review cold case files, open new investigations or identify missing
persons from stored human remains. We believe that the bulk of our investigative
support will come through local and regional police, fire and detective agencies
that do not require any federal funding to use our services and technology. We
will however, continue to pursue much larger applications for our technologies
on a global basis and will participate in several forensic and biometric venues
in the remainder of 2005 that offer us a broad platform exposure to the world
market. We are also seeking distributors of our products and services on a
global basis applying our technology wherever the need could arise.
Jever .....
News Story ......
Does it involve DNAWITNESS? ......
HMMMMMMMMM --- GEO
Yes I see it Golf4 ....eom
Dr Fud .....
Once again ......
You are a waste of time .....
BUY BUY --- GEO
Dr Fud ......
I am not pumping .......
I have noticed an increase in revenue ......
I have also noticed that the ......
last 3 months over a 9 month period ......
was the most profitable ......
with this in mind ........
I can ascertain that DNAG is moveing forward .....
with regards to revenue .......
Now we have 3 new labs under the DNAG "umbrella" ......
We have patents from all 3 of these new labs .......
we have our ADMIXMAP patent .......
Remember that one? ......
the one you "stated" was DOA .......
you are a funny/sick man Dr FUD ......
DNAG is Growing ......
and I'm all for it ........
This Companies direction ......
is towards BILLIONS in Revenue ......
I'm invested long term ......
and will be Holding my position ......
and buying the deals presented .......
I believe Richard is putting together ......
A "Fast Tracking" RD Team .......
I AM STAYING THE COURSE --- GEO
Frog .........
You seem to stand on your "apple crate" .....
and intice investors to believe that the SP ......
reflects the "worth of a Company" .......
I disagree ............
If it were not for the phrase ........
"under valued" ............
I WOULD NOT HAVE AN ARGUEMENT --- GEO
TORONTO, Canada | May 24, 2005
Ellipsis Biotherapeutics Corporation announced today that it now offers SNP genotyping using both the Illumina GoldenGate™ and Beckman Coulter SNPstream™ technologies.
“The addition of the Illumina system to our existing SNPstream platform allows us the unique opportunity to accomodate all SNP genotyping projects, ranging in size from quite small to very large”, commented Laurence Rubin, CEO of Ellipsis. “We are very excited to offer this complete suite of SNP genotyping solutions to our clients”.
Ellipsis Biotherapeutics Corporation was founded in 1997 to commercialize the disease gene discovery efforts of its founders, primarily in the area of inflammatory disease. Since then, it has leveraged its expertise in SNP genotyping to provide high quality service to a variety of clients in academic, government and industrial research settings. For more information, see the company’s website at www.ellipsisbio.com, or contact genotyping@ellipsisbio.com.
TORONTO, Canada | April 22, 2004
Findings Published in Nature Genetics.
Ellipsis Biotherapeutics Corporation, a drug and diagnostics discovery company, together with academic collaborators, has isolated novel genes that predispose people to development of Crohn's disease. Their findings appeared online April 11 in the journal Nature Genetics (www.nature.com/ng/) and are published in the current issue of the journal.
"Isolating this gene is a critical step towards improved diagnosis of this disease and developing better therapies for Crohn's sufferers, who have an urgent need for better treatment" says Katherine Siminovitch, President and Chief Operating Officer of Ellipsis. Crohn's disease is an inflammatory bowel disease of increasing prevalence in industrialized nations. Existing treatments are considered unsatisfactory, often requiring recurring hospitalization and surgeries.
The Crohn's discovery was made using Ellipsis' genetic analysis technologies to identify genes using DNA samples from family groups. The identified genes produce proteins that sit on the surface of cells lining the gastro-intestinal tract and regulate how substances enter and exit these cells. In a majority of Crohn's disease patients, these proteins function improperly and allow toxins easier access to the cell.
The ability to test for this altered protein will help physicians distinguish between Crohn's disease and ulcerative colitis, the other major form of inflammatory bowel disease known. The alteration discovered by Ellipsis and its collaborators is not present in ulcerative colitis, so this gene alteration provides a diagnostic test to help distinguish between the two diseases. Ellipsis anticipates that this information can also be used to diagnose Crohn's disease at an earlier stage and to develop new approaches to treatment. The discovery of these novel genes will also enable the development of small molecules that can regulate these disease pathways.
"We are very excited about this discovery," says Siminovitch. "It provides further demonstration of the success of Ellipsis technologies and sheds light on the biological processes that lead to many chronic inflammatory conditions, such as Crohn's disease and rheumatoid arthritis, which have similar causes even though the target organs differ."
Ellipsis Biotherapeutics Corporation is a privately held drug and diagnostic discovery company developing novel medicines for human diseases where existing therapies are unable to address patient needs. The company's lead programs are in Alzheimer's Disease and Inflammatory Bowel Disease, where new treatment regimens are needed not only to treat symptoms, but to prevent and cure the underlying disorder. Through both independent programs and strategic alliances, Ellipsis intends to commercialize its discoveries and make better medicines for patients.
Ellipsis Biotherapeutics Corporation to broadcast SNP genotyping technology web seminar hosted by Beckman Coulter, Inc.
TORONTO, Canada | April 15, 2004
THAT SHOULD INFLAME SOME HERE --- GEO
7 ....
During 2005, we entered into agreements with seven new
distributors to sell our ancestry products. One of our new distributors
accounted for approximately $160,000 of sales during the first nine months of
2005.
WE HAVE JUST BEGUN --- GEO
SUPER EPO .....
We plan to begin development of our new product and have GMP
material ready for early stage pre-clinical development work by or during the
first quarter of 2006 in accordance with our licensing agreement with BIDMC.
ENCOURAGEING --- GEO
So many of us on the same bed ........
So much to look forward to ......
Some would like to keep checking .......
under the bed ........
some would like to keep looking .......
at the roof ........
for those who have dimminished the ........
importants of what is going on ........
should leave JMHO ......
There is a pattern forming .......
M/A has been on the rise .........
We are growing LARGER and LARGER ........
Something is going on ........
We are turning ourselves into one HECK of a RD Co. ........
I thought the #'s looked good, over all ........
it was what I was expecting ........
DNAG understands the importants of Marketing ..........
and will take steps towards this goal ......
This is the START ........
Long term investors will be rewarded .......
take advantage of the "power of the basher" .......
buy at these incredible low SP .........
and HOLD ........
many of us here are doing it ......
we are accumulateing ........
and our Holdings as a "collective" ......
are Huge ........
When (not if) we have a Revenue deal ........
We are on our way ........
Don't let any one fool you ......
DNAG IS TAKEING THE RIGHT STEPS GOING FORWARD --- GEO
ann ......
The 10k .....
will be where we see .....
The importants of the Trace M/A .......
also DNAWITNESS .......
as well as ANCESTRYBYDNA .......
I'm not looking for huge numbers .....
but would be very "happy" .......
To see these products moveing forward .......
DNAWITNESS is the "porche" ......
when it comes to DNA profileing .......
Results from the World Forensic Meeting .......
May not show up until the next 10k ......
but it will show up .......
I'm sure we now have 3 labs ........
that are hard at work .......
putting DNAG on the map .......
but .......
I'm pretty sure we will see what .......
Trace has been able to do for us on our bottom line .......
Richard has stated that he would like to see ........
DNAWITNESS as well as ANCESTRYBYDNA hold their own ......
before proceeding with our Pharma division .......
We will also see BIO's SP reflected on our bottom line ......
and we all know how well it's doing (wink wink-nudge nudge) ....
This may take some time to "really" get going .......
but I am getting ready long term .......
I am ......
HOLDING AND BUYING THE DEALS --- GEO
Excellent find; regarding Timothy Yeatman.....ifida
SARASOTA, Fla., March 29 /PRNewswire-FirstCall/ -- DNAPrint genomics (BULLETIN BOARD: DNAP) (the "Company") of Sarasota, FL today announced that it has formed a multi-faceted pharmacogenomics program with the H. Lee Moffitt Cancer Center & Research Institute at the University of South Florida. The program will aim to develop and implement new clinical tests for predicting patient response to various cancer chemotherapies.
Moffitt physicians and scientists are teaming with DNAPrint to identify genetic variants that underlie poor patient response to various chemotherapies, and to implement new clinical tests at the Center combining these variants with other biomarkers from gene-expression, proteomics and epidemiological research. The aim of the tests will be to predict patient chemotherapy response from the DNA before the commencement of the chemotherapy, so that patients with a genetic proclivity for poor or non- response can be spared from exposure to ineffective therapy. With the newly signed agreement, both organizations have teamed to make an important stride towards their goal of enabling a more personalized, safe and effective modality of cancer treatment for our current generation of cancer patients.
The program is multi-faceted and presently defines study in several cancer areas and clinical programs. Research will draw from several ongoing clinical trials and epidemiology research projects underway at the Center. A primary area of focus for the program is colorectal cancer, where DNAPrint will work with primary investigator Dr. Timothy Yeatman, Moffitt's Associate Center Director for Clinical Investigations. DNAPrint will implement its proprietary ADMIXMAP genetic discovery platform to define gene sequences predictive for response to two anti-cancer treatments, XELOX and XELIRI. Though representing current FDA-approved therapies for metastatic colon cancer, approximately 50% of patients fail to respond and given the poor prognosis associated with non- response, there is a dire need for tools capable of predicting response beforehand. The study design will aim to first discover and then evaluate the predictive power of predictive Single Nucleotide Polymorphism (SNP) markers in tandem with biomarkers from gene expression chip and proteomics research currently under way at Moffitt. The first colon cancer study will involve 100 patients. Other phases of this particular project will permit a retrospective alignment of genetic risk and epidemiologic factors, and prospective evaluation of chemotherapy response prediction in the setting of GLP and FDA-approved clinical trial setting.
Over all of the program areas, the collaboration will combine Moffitt oncologists, research scientists, mathematicians and software engineers with DNAPrint computer scientists, molecular biologists and population geneticists, and draw upon DNAPrint's pharmaceutical, clinical and regulatory expertise. Moffitt will contribute gene expression and proteomics data resources currently in development and DNAPrint will contribute its ADMIXMAP platform and SNP analysis for mapping the genetic determinants of variable drug response by harnessing the power of human population genetic structure. "We have identified several clinical projects at the Moffitt that are of keen commercial and social interest," said Dr. Hector J. Gomez, MD, PhD, Chairman of the BOD and Chief Medical Officer of DNAPrint genomics, Inc. "Each of these programs offers us the opportunity to advance cancer treatment in a significant way," he said. Recent (November 2003) FDA guidance regarding pharmacogenomics technologies promulgate that if markers are validated using well understood markers in legitimate clinical environments, genetic tests derived from those markers should be included in new drug applications.
ADMIXMAP-ADVANCEING CANCER TREATMENTS IN A SIGNIFICANT WAY --- GEO
Two things to notice here .....
September 2004: Genomics Collaborative Inc (recently acquired by SeraCare Life Sciences) and Kenna Technologies complete Phase I SBIR collaboration with anticipated success. The results of this 6 month project provide clear validation that computational simulation of the molecular and cellular networks involved in bone remodeling (Kenna's BoneFusion) accurately identified which gene among 83 possible candidates linked to osteoporosis is likely to be responsible for inherited predisposition to early onset osteoporosis. September 2004: Genomics Collaborative Inc (recently acquired by SeraCare Life Sciences) and Kenna Technologies complete Phase I SBIR collaboration with anticipated success. The results of this 6 month project provide clear validation that computational simulation of the molecular and cellular networks involved in bone remodeling (Kenna's BoneFusion) accurately identified which gene among 83 possible candidates linked to osteoporosis is likely to be responsible for inherited predisposition to early onset osteoporosis. Most notably, the identification of the linked gene was accomplished in a total of only 8 months, in contrast to years for conventional candidate gene or linkage methods.
MOST NOTABLY, VERY IMPORTANT --- GEO
Cosmiclifeform ......
I couldn't agree more .......
Our Management and staff can/will ......
take a lot of pressure of R/D for big Pharma .....
and with Kenna on board ......
We may have the ability through "Computer-Enhanced programs"....
To "fast track" a lot a drugs ......
HUGE POTENTIAL --- GEO
SeraCare has two major business divisions: BioPharmaceutical, serving the therapeutic and research markets through three subdivisions, and Diagnostics, serving the diagnostic test kit manufacture market through two subdivisions. These business divisions are broken down further, as shown below:
BioPharmaceutical
(1) BioProcessing includes human and animal cell culture media components, processed plasma, and Human Serum Albumin for use by pharmaceutical developers and therapeutic drug manufacturers. This department also provides living cells derived from blood draws, most commonly T cells and PBMCs, for research purposes.
(2) The SeraCare Global Repository® provides normal and disease state human serum, plasma, DNA, RNA, and tissue, as well as detailed matching medical data to the biopharmaceutical industry. All SeraCare Global Repository® collection protocols are IRB-approved, and samples are compliant with current HIPAA regulations protecting patient privacy. The SeraCare Global Repository® is collected through an extensive Physician Network, enabling us to perform prospective collections. The SeraCare Global Repository® has over 600,000 biological specimens from 120,000 patients.
Our powerful in-house search engine, GCI Access™, can provide access to all banked samples. The SeraCare Global Repository® comprises collections in various types of cancer, autoimmune, metabolic, infectious, and cardiovascular disease states. For more information, please also visit www.genomicsinc.com.
(3) BBI Biotech Research Laboratories provides a broad range of research support services to the government and commercial clients. Within BBI Biotech, there are three major groups: Repository, Virology, and Molecular Biology. For more information, please also visit www.bbii.com.
Diagnostics
(1) SeraCare Diagnostic Products (Oceanside, CA) include blood-derived base matrices, positive and negative control sera, and various purified proteins used in the manufacture of in vitro diagnostic products. We also offer specialty antibody plasma, which is available in single donor units and can be drawn to meet your specifications. Most items are available in either plasma or serum, and we can provide them as a negative for diluent or for controls. Purified Human Antigens are available of the highest quality and are offered at extremely competitive prices.
We exclusively distribute Bovine Serum Albumin from Proliant, including products ranging from Standard Grade to Low Endotoxin biotech grades. Our Bovine Serum Albumin-based products have complete traceability from bovine plasma collection through the manufacturing of the finished product, giving our customers great security in the safety and purity of our products.
We also distribute a full line of in vitro stabilizers from SurModics, a leading surface modification company.
(2) BBI Diagnostics (West Bridgewater, MA) provides a comprehensive line of quality control products used in infectious disease testing. These products are used by test kit manufacturers, infectious disease researchers, regulatory agencies, independent clinical laboratories, hospitals, public health laboratories, blood banks, and plasma collection centers to help ensure accurate and precise infectious disease test results. For more information, please also visit www.bbii.com.
The employees of SeraCare Life Sciences, Inc. are dedicated to making the best possible products for their customers and providing excellent customer service. With this dedication and service, we hope to become your choice for Diagnostic, Therapeutic, Cell Culture, and Research products.
BIG DATA BASE, AS WELL AS KIT MAKER --- GEO
Hopeless ....
I thought our Debate .......
was regarding ......
Richard talking to the FDA ......
You have no sense of direction, pal ......
Perhaps you should get out of DNAG ......
and proceed towards something less stressful ......
like perhaps .....
BELLY DANCEING --- GEO
Hopeless .....
Ahhhhhh ......
but pennies make dimes .....
and dimes make dollars .......
WHATS IN YOU WALLET --- GEO
NEWS OUT .....
DNAPrint Genomics and SeraCare's Genomics Collaborative Combine to Improve Outcome for Ovarian Cancer Treatment
11/14/2005 7:00:06 Am
SARASOTA, FL AND OCEANSIDE, CA, Nov 14, 2005 (MARKET WIRE via COMTEX) -- DNAPrint(TM) genomics, Inc. (DNAG) and the Cambridge, Mass.-based Genomics Collaborative Division of SeraCare Life Sciences, Inc., today announced that they have begun collaboration on a project designed to improve treatment for patients with ovarian cancer.
"The goal is to identify genetic factors that will enable physicians to predict the outcome and efficacy of carboplatin/tamoxifen treatment, a standard therapy for victims of breast cancer," stated Hector J. Gomez, M.D., Ph.D., Chairman and Chief Medical Officer of DNAPrint genomics. "Combining Genomics Collaborative's extensive network of physician-managed centers with DNAPrint's proprietary genetic testing, the genetic characteristics of 200 women will be studied by comparing those who responded to a standard carboplatin/tamoxifen regimen for breast cancer with those who did not."
"We anticipate that the study's findings may enable physicians to identify likely non-responders before initiation of carboplatin/tamoxifen therapy so that an alternative treatment can be utilized from the outset," stated Kevin Krenitsky, M.D., Senior Vice President and Division Head of Genomics Collaborative. "We hope to improve the outcome of treatment for patients afflicted with this challenging condition."
This marks the second collaborative project between DNAPrint and Genetics Collaborative.
NOW MORE DD IS NEEDED ... LOL --- GEO
Hopeless .....
Since we seem to be heading ......
down a different road .....
Richard has had talks regarding ......
the "Standards and Practices" of this "new" science .......
Both with the FDA and NIH .......
TWST: It sounds like, longer term, the real opportunity is on the
pharmacogenomics side.
Mr. Gabriel: Well, the same thing applies in pharmacogenomics. Think of
it this way: Take an African-American medical patient who enrolls in a
trial for a drug that works specifically, let's say, for high blood
pressure. This is a condition that occurs more frequently in African-
Americans. But as it turns out, the patient's ancestors were mostly
Native American or East Asian; perhaps there was an African-American
great, great grandfather somewhere along the line whose characteristics
the patient inherited. The patient lives in the African-American
community and cannot be expected to change his or her social or
political affiliations just because of a DNA sample. The real problem is
that the patient may not have inherited the required gene that is
beneficial for the drug treatment, and the drug might actually do more
harm than good. What we want to do is optimize the drug development
process with what we call 'Theranostics' ' genetically tested drugs
appropriate for specific individuals and well-defined population
sectors. Our goal is to help insure that patients receive the
appropriate medicine and proper dosage the first time around. This takes
us back once again to the case in point where social/political
affiliations come into direct conflict with inherited ancestors. Your
genes have nothing to do with your political voice. As a matter of fact,
they don't care. But understanding a person's ancestry or genetic
inheritance is extremely important to the doctor and the patient. That's
really what our focus is. We have taken up the banner and actually had
discussions with the FDA.
Dr. Frudakis wrote about this as part of a discussion panel for current
pharmacogenomics guidelines, which includes hints about ancestry and
genetic inheritance. We're proponents of having an open dialogue with
the FDA and with the National Institutes of Health (NIH) about the
importance of genetic ancestry.
TWST: Is anybody else working in the same space?
Mr. Gabriel: Oh, certainly. The NIH itself has a pharmacogenomics
branch. The head of Human Genome Sciences has come forward on the
importance of genetic ancestry; the head of Celera Genomics has spoken;
Affymetrix and Perlegen Sciences are in this. There's a lot of
competition in this field. We just happened to start early, and we
happen to believe that diversity is a human quality that is a wonderful
trait ' but that it also brings along inherited markers that maybe
aren't so good from a medical standpoint. And for the medical field, we
think this is the only way to rationalize drugs.
TWST: Is there broad understanding and agreement on this?
Mr. Gabriel: There's a lot of debate, mostly around geopolitical and
social concerns ' which are legitimate. There is absolutely no question
about the legitimacy of these concerns. We live in a democratic society,
and in order to have a debate we need to have an open dialogue about it.
There are already laws on the books that offer remedies for many of the
concerns. I would say that if an insurance company discriminates against
an individual because of an inherited marker and denies that person
insurance, it could result in hundreds of millions of dollars' worth of
lawsuits. At the same time, the federal government wouldn't allow this
type of discrimination to begin with. So there's plenty of legislation
in place to protect individuals. There are independent review boards at
hospitals, patients' bills of rights ' a lot of legislation is in place.
You cannot discriminate against individuals in the United States and get
away with it.
TWST: What type of standards does DNAPrint genomics set for itself?
Mr. Gabriel: We operate under the highest ethical standards and have a
strict code of ethics. DNAPrint genomics has a unique database that
gives us an understanding of families and how they're related, but we
don't divulge any of that information. Our customers' data is private.
If they ask us to destroy the DNA we do ' though some people ask us to
keep it because, for historical reasons, they want to make sure that if
they're doing a family genealogy they'll have DNA samples from all the
members of the family for comparison. And in that case we keep those
DNAs.
TWST: Is all that going to inhibit development?
Mr. Gabriel: Starting before Dr. Mark McClellan's tenure at the FDA, but
really under his leadership, this issue has come to the forefront. I
have to say that the FDA has taken an absolutely stellar lead in
encouraging this dialog. And along with that, the NIH has been also a
strong promoter and will continue to be. I think it's in the best
interest of all mankind to understand what your heritage is and what
diseases are inherited.
TWST: Tell us about the company's management and its goals for the
future.
Mr. Gabriel: We've all been working at this for some time. I've been in
the pharmaceutical business for 20 years.
Dr. Hector Gomez, our Chairman and Chief Medical Officer, has been in it
all of his life. He has 11 drugs under his belt; I have four or five and
probably have been involved with 60 or 70 ' from discovery all the way
to approval ' over the course of my career. There are three or four
drugs on the market now that have gone through my previous company's
hands. We're dedicated individuals, and I thank our shareholders for
believing in our company. And that, quite honestly, is why we're looking
for acquisitions. We want to build our revenue, and we either build our
revenue through sales, selling a new technology into a market, which is
hard, or we acquire it ' and we're aggressively looking at both because
the goal is to boost shareholder value. I myself am a shareholder.
TWST: What are you looking for in the way of acquisitions?
Mr. Gabriel: Companies that bring accreditation to us in the
pharmaceutical area as well as in the forensics area. We are looking
across a broad spectrum of companies, both public and private.
TWST: Are there any milestones that you can set out for the next year or
two?
Mr. Gabriel: Our milestones have always been the same. They haven't
changed from the first day I came onboard. The goal is to make the
company profitable as soon as possible, and we're pursuing that by
developing products that we can get out into the market. Our new
DNAWITNESS test kit is just an example. We continue to build our
database. We have a 2,500 photo database and we collect samples. We're
building our product portfolios to make our products attractive to the
customers in genealogy as well as in forensics, and we will continue to
do that. Pharmacogenomics is a longer haul, but it certainly offers a
much greater point of return when a product is approved and is accepted
by the market. So we look at it in a three-step fashion. We look at our
consumer products market, building our continued consumer base, and we
have probably sold, oh, I don't know, 11,000 or 12,000 samples, or kits
into that market, and our long-term goal is to have, quite literally,
millions of those. So we will be a very unique company in that we will
have analyzed, literally, millions of DNA samples on a blind basis '
blind samples. We know nothing about the individuals; we just get a DNA
sample, and we report on it back to them. We also think there's a
tremendous opportunity in forensics. In the investigation of cold cases
-' and there's a backlog of hundreds, if not hundreds of thousands of
such cases ' our technology can be used to help categorize those cases.
Certainly categorizing DNA samples is important for the Innocence
Project. If a crime scene sample shows that the suspect is Caucasian and
the individual who's incarcerated is African-American, obviously, you
move his DNA to the top of the pile and you do the match and you free
him. So there's plenty of opportunity in those two markets for growth.
It's steady and consistent growth. It will, however, not be the bell
ringer. The real bell ringer for this technology has always been in the
pharmaceutical area, really matching the patient with the doctor and
with the therapy through 'Theranostics.' That's what this technology can
do. It can actually put the doctor and patient back in control of the
pharmaceuticals that are being administered for the disease that's being
treated. We can do this one step at a time, one drug at a time. We'll
just proceed down that path and have an open dialog with the FDA, the
NIH and move our technology forward. In addition, we're looking at
licensing opportunities for therapeutics as well ' in other words,
talking to people about drugs that we can bring in. We want to run
clinical trials of drugs along with our technology, and instead of
having 40% or 60% efficacy we could have up to 95% efficacy, which means
longer product life. That's a novel concept, and an important one.
Especially when patents expire, the question always is, how you keep
generics out. Well, how you keep generics out is that you have a product
that is 95% efficacious. That builds brand loyalty, and people don't
want to change. Aspirin has been around for a couple of hundred years,
and everybody knows Bayer aspirin; or Tylenol, anyone can make Tylenol,
but no one thinks of acetaminophen, people think of Tylenol. That's
brand loyalty. It's something that's been around in the pharmaceutical
industry itself, and you do that by making a product that, when you take
it, the result is there. You take Bayer aspirin, you know what you get;
you take Tylenol, you know what you get. So if you have a disease and
you have a drug that treats the disease, the doctor knows that it's an
efficacious drug, and if you match the patient to the drug and it works,
then that's what's going to happen. That's how scrips are generated.
TWST: Thank you. (TJM)
SO THERE --- GEO
Hopeless .....
How do YOU know .....
Richard has not been in touch .....
with the FDA? ......
My DD shows that he is in touch with the FDA ......
on a regular basis .....
So I GUESS your saying ......
Untill the FDA states ......
that they have been in touch with Richard .......
Richard has not been in touch ......
with the FDA .......
WEAK, VERY WEAK --- GEO
Our People at Kenna
Barbara Handelin, Ph.D., President, CEO & Co-Founder, is an internationally recognized business executive and scientist with 13 years of executive management experience in R&D and product commercialization in the biotech, bio-pharmaceutical, and genomics industries. Dr. Handelin’s previous business experience includes company start-up and financing (Genovo, a gene therapy company), executive consulting, and building a worldwide business division (DNA Diagnostics Lab at Integrated Genetics, now Genzyme Genetics).
L. Tandy Herren, Ph.D., Chief Technology Officer & Co-Founder, is an expert in interface technologies and artificial intelligence with over ten years of applied biological modeling experience in the research (Southwest Research Institute) and the biotechnology (Interleukin Genetics) industries. Dr. Herren is co-author of the issued U.S. patent that supports Kenna’s interface technology.
Paula Enrietto, Ph.D., Director of Biological Sciences, is an expert in molecular and cellular biology (focus in cancer) with over 30 years of experience in biological research and over seven years of management experience in biotech start-up companies (Integrated Biosystems, a biotech company, and Genomica Corp, a bioinformatics company). Dr. Enrietto has a proven track record in delivering computer-based research tools for drug discovery. Previously, Dr. Enrietto was a tenured professor of Microbiology at the State University of New York at Stony Brook, and has authored more than 40 scientific publications.
Robert E. Blomquist, Director of Business Development & Marketing, has over 16 years of international executive management experience in the biotech (Pharmacia Biotech), genomics (Eurona Medical), bioinformatics (Genomica), diagnostics (EG&G Wallac, Pharmacia Diagnostics) and life science consulting industries. Mr. Blomquist’s business experience includes company start-up and financing (Medictor Technologies), business development, general management, sales and marketing management (Wallac Oy, Canada).
Helga Kautsky, C.P.A., Chief Financial Officer, has over 20 years of financial management experience in the pharmaceutical (SmithKline Beecham, Astra-Merck), consulting (Booz Allen & Hamilton Inc. and Price Waterhouse), and technology industries. Ms Kautsky has provided financial and treasury management services for start-up and emerging technology companies as CFO/Controller through Pickering Financial, Ltd., Ms. Kautsky’s sole proprietorship consulting practice.
Key Advisors and Directors
David E. Housman, Ph.D. - Co-Founder & Advisor. Dr. Housman is the Ludwig Professor of Biology at the Massachusetts Institute of Technology and a National Academy of Sciences and the Institute of Medicine fellow. He serves on Medical and Scientific Advisory boards of five foundations, including the Merck Genome Institute, the Cure Huntington's Disease Institute and the National Neurofibromatosis Foundation. Dr. Housman was the scientific co-founder of one of the earliest biotechnology companies, Integrated Genetics, (1981) followed by Variagenics, a privately held pharmacogenomics company
Richard Sherman, Esq.: Mr. Sherman is a Managing Officer of QED Technologies, Inc., a strategic consulting firm for life science-based companies, a Principal of CIP Capital Management, Inc., and as Counsel to the law firm of Goodsill, Anderson, Quinn & Stifel, in Honolulu, Hawaii. Prior to forming QED, Mr. Sherman was Deputy General Counsel at SmithKline Beecham Corporation (now GlaxoSmithKline). Mr. Sherman has served as Director of IBAH, Inc., Sparta Pharmaceuticals, Inc., and Cytomed, Inc. Currently, he is a Board member of Pennsylvania Biotechnology Association, member of the Board of Trustees of the Crossroads School, and Director of Biophage, Inc., of Montreal, Canada, Aquasearch, Inc. of Kona, Hawaii, and Hawaii Biotechnology Group, Inc. of Honolulu, Hawaii.
Romeo Bachand, M.D., Ph.D.- Director: Dr. Bachand is currently Senior Vice President and Chief Scientific Officer at Auxilium, A2, Inc., Prior to joining Auxilium, Dr. Bachand was at Abbott International over a 14 year period including most recent post as Vice President, Global Clinical Development, Vice President, Scientific & Medical Affairs and Quality Assurance and Venture Head for the Macrolides division. Dr. Bachand serves on the Scientific Advisory Committee of Genomics Collaborative, Inc. (Cambridge, Mass), the New York Medical College Graduate School of Health Sciences & Sir Patrick Dun’s Institute (Dublin, Ireland) Advisory Board (New York, NY) and the Pharmaceutical Foundation Advisory Council at University of Texas, Austin as well as on the Board of Trustees of the American Heart Association.
James McCormick, M.D.- Director: Dr. McCormick is Director of Laboratory Medicine, Swedish Covenant Hospital and Chairman of the Board, LifeCenter on the Green, Inc. (affiliate Swedish Covenant). Dr. McCormick holds 42 patents for laboratory medicine products, which he has licensed and directly helped to commercialize over the last 45 years. Dr. McCormick’s deep experience in the executive management of high quality health care is reflected by his status in several prestigious national organizations. He recently finished serving on the board of the National Museum of Health and Medicine, is a Distinguished Fellow of the American College of Physician Executives and a Fellow of the American College of Healthcare Executives.
SOMETHING TO THINK ABOUT --- GEO
Just a Reminder .....
New Super EPO Test/Drug Combination Enters Preclinical Development Stage
SARASOTA, Fla., Sept. 27, 2005 (PRIMEZONE) -- DNAPrint(tm) genomics, Inc. (OTCBB:DNAG) today announced the completion of initial research for the production of PT-401, a more powerful version of the anemia drug Erythropoietin (EPO), which has advanced into the preclinical development stage for the Company's first pharmaceutical product.
"Our research surveyed several potential host cells for the production of PT-401," stated Hector Gomez, M.D., Ph.D., Chairman and Chief Medical Officer of DNAPrint genomics. "We have selected one that the research indicates will provide superior glycosylation, which is critical for the processing of PT-401. We anticipate that this will lead to greater therapeutic efficacy and later on will be beneficial to expediting regulatory approval. In addition, we have optimized the structure of the gene encoding PT-401, thus providing excellent production efficiency and an optimal structure/activity profile of the active compound. Our production schedule remains on target."
DNAPrint(tm) obtained an exclusive worldwide license from Harvard Medical School's Beth Israel Deaconess Medical Center (BIDMC) in February 2005 for the development of a "Super" EPO, a more potent and longer acting form of Erythropoietin (EPO), which has a worldwide market exceeding $10 billion and which is growing at an average annual rate of 21%. Production of a Super EPO dimer is central to DNAPrint's overarching strategy to utilize recent genomics and chemistry advances to develop next-generation test/drug combinations called "Theranostics," which maximize efficacy and minimize side effects by tailoring and customizing medication for specific individuals and well-defined population sectors. In June 2005, DNAPrint selected Proteos, Inc., to handle pre-clinical analysis of PT-401 and to manufacture the first batch of the new drug.
WE ARE MOVEING FORWARD --- GEO
Jever ......
I'm guessing .....
your talking about the 10k? .....
CURIOUS --- GEO
Puursuing Start-Ups ....
Personalized Medicines: The Coming Revolution in Longevity
Medical experts say that treatments will soon be customized for individual patients based on their genetic makeup or other medical measurements.
This will allow you to get the drug that work best for you ailment without the risk of serious side effects.
Imagine taking one pill that can ease your back pain, and lower your cholesterol at the same time. Or one pill that can prevents your migraine, relieves your arthritis, and clears up your allergies.
Before long your doctor will be able to prescribe side effect-free, customized medications specifically for you that will be able to treat any combination of ailments.
Scientists are now finding a number of gene variations that help predict who will respond positively to a drug or who will suffer side effects.
Most drug companies now routinely collect DNA samples from patients in clinical trials to look for such markers.
Like a tailored Giorgio Armani suit, future personalized medicines will be prescribed to fit a patient's unique genetic profile.
Today genetic science is highly controversial. And medical ethicists worry that companies will discriminate by denying work, health insurance or pricey drugs to patients whose genetic profiles show they might be prone to disease.
Regardless of this, in March the FDA issued guidelines to encourage drug companies to pursue personalized medicine. The agency is also adding information about genetic tests to the labels of a few drugs.
Herceptin was created for treatment for women who have this specific type of breast cancer.
There are also drugs for particular groups of people.
Today's personalized medicines are referred to as pharmacogenetics. Pharmacogenetics is treating the same disease differently in particular groups of people rather than an individual.
BiDil, created by a young biotech company, NitroMed (NASDAQ:NTMD), is a milestone in the development of personalized medicine.
BiDil is a treatment for heart failure specifically designed for African-Americans.
This is the first drug FDA-approved specifically for a racial group.
Now, more than ever, investors and companies are clamoring for similar foothold in personalized medicine. Interest in the sector is growing for several reasons.
New software and other technologies help researchers design better experimental drug tests to pinpoint problems before drugs reach the market. This will help to avoid future problems such as Merck's (NYSE:MRK) withdrawn painkiller Vioxx.
Prices paid by insurance companies are soaring for remedies that are ineffective in as many as half of patients.
It has been estimated that U.S. health costs could double in the next eight years, putting industries such as automakers further behind foreign competitors with lower employee medical costs. This is putting severe pressure on drug manufactures to develop medicines that work better.
Drug companies also hope personalized medicine will produce new treatments to boost sluggish pipelines or open new markets for tech companies selling to the health industry.
The Personalized Medicine Coalition, launched last year, now has over 50 members.
They include established biotech firms such as Amgen (NASDAQ:AMGN) as well as traditional drug manufactures such as Abbott Laboratories (NYSE:ABT) and Pfizer (NYSE:PFE).
The personalized medicine market is bigger than curing ailment.
Customized elective drugs such as hair growth, weight loss, and erectile dysfunction drugs will also become personalized.
New options that will affect lifestyle, prolong life, and restrict aging are before us.
Drug companies are currently pursuing start-ups that are leveraging advances in genetics to find medicine's holy grail: drugs that are safer, cheaper and more effective because they're fine-tuned for patients
HOLD AND BUY THE DEALS --- GEO
MattG ....
With a higher share price .....
less shares needed to finance .....
With Biofrontera AG we should have a Sp above .05 JMHO .......
We will be going higher .....
and higher .....
and higher .....
and higher .....
and higher .....
ETC ETC ETC --- GEO
Personalized Medicine ......
More Articles:
http://www.cbinet.com/show_conference.cfm?confCode=HB545
A GOOD READ --- GEO
Personalized Medicines: The Coming Revolution in Longevity
Medical experts say that treatments will soon be customized for individual patients based on their genetic makeup or other medical measurements.
This will allow you to get the drug that work best for you ailment without the risk of serious side effects.
Imagine taking one pill that can ease your back pain, and lower your cholesterol at the same time. Or one pill that can prevents your migraine, relieves your arthritis, and clears up your allergies.
Before long your doctor will be able to prescribe side effect-free, customized medications specifically for you that will be able to treat any combination of ailments.
Scientists are now finding a number of gene variations that help predict who will respond positively to a drug or who will suffer side effects.
Most drug companies now routinely collect DNA samples from patients in clinical trials to look for such markers.
Like a tailored Giorgio Armani suit, future personalized medicines will be prescribed to fit a patient's unique genetic profile.
Today genetic science is highly controversial. And medical ethicists worry that companies will discriminate by denying work, health insurance or pricey drugs to patients whose genetic profiles show they might be prone to disease.
Regardless of this, in March the FDA issued guidelines to encourage drug companies to pursue personalized medicine. The agency is also adding information about genetic tests to the labels of a few drugs.
Herceptin was created for treatment for women who have this specific type of breast cancer.
There are also drugs for particular groups of people.
Today's personalized medicines are referred to as pharmacogenetics. Pharmacogenetics is treating the same disease differently in particular groups of people rather than an individual.
BiDil, created by a young biotech company, NitroMed (NASDAQ:NTMD), is a milestone in the development of personalized medicine.
BiDil is a treatment for heart failure specifically designed for African-Americans.
This is the first drug FDA-approved specifically for a racial group.
Now, more than ever, investors and companies are clamoring for similar foothold in personalized medicine. Interest in the sector is growing for several reasons.
New software and other technologies help researchers design better experimental drug tests to pinpoint problems before drugs reach the market. This will help to avoid future problems such as Merck's (NYSE:MRK) withdrawn painkiller Vioxx.
Prices paid by insurance companies are soaring for remedies that are ineffective in as many as half of patients.
It has been estimated that U.S. health costs could double in the next eight years, putting industries such as automakers further behind foreign competitors with lower employee medical costs. This is putting severe pressure on drug manufactures to develop medicines that work better.
Drug companies also hope personalized medicine will produce new treatments to boost sluggish pipelines or open new markets for tech companies selling to the health industry.
The Personalized Medicine Coalition, launched last year, now has over 50 members.
They include established biotech firms such as Amgen (NASDAQ:AMGN) as well as traditional drug manufactures such as Abbott Laboratories (NYSE:ABT) and Pfizer (NYSE:PFE).
The personalized medicine market is bigger than curing ailment.
Customized elective drugs such as hair growth, weight loss, and erectile dysfunction drugs will also become personalized.
New options that will affect lifestyle, prolong life, and restrict aging are before us.
Drug companies are currently pursuing start-ups that are leveraging advances in genetics to find medicine's holy grail: drugs that are safer, cheaper and more effective because they're fine-tuned for patients
10K - UP UP and AWAY --- GEO
loch3 .....
Gather speed? .....
Oh yes in deed .......
We are going to hear a "lot" ......
publicly, about Personal Medicine ......
Many know nothing about us ......
BUT THEY WILL --- GEO